Evidence map›Paper›PMID 30746243›Full record

ReviewJournal of thoracic disease2018

Clinical manifestations, diagnosis, and treatment of ischemic mitral regurgitation: a review.

Néstor Báez-Ferrer, María Manuela Izquierdo-Gómez, Belén Marí-López, Javier Montoto-López, Amelia Duque-Gómez, Javier García-Niebla, Julio Miranda-Bacallado, Alejandro de la Rosa Hernández, Ignacio Laynez-Cerdeña, Juan Lacalzada-Almeida

Open access · hybridAbstract readReview
In one paragraph

Review in Journal of thoracic disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Néstor Báez-FerrerDepartment of Cardiology, Hospital Universitario de Canarias, Tenerife, Spain.
María Manuela Izquierdo-GómezDepartment of Cardiology, Hospital Universitario de Canarias, Tenerife, Spain.
Belén Marí-LópezDepartment of Cardiology, Hospital Universitario de Canarias, Tenerife, Spain.
Javier Montoto-LópezDepartment of Cardiovascular Surgery, Hospital Universitario de Canarias, Tenerife, Spain.
Amelia Duque-GómezDepartment of Cardiology, Hospital Universitario de Canarias, Tenerife, Spain.
Javier García-NieblaServicios Sanitarios del Área de Salud de El Hierro, Valle del Golfo Health Center, El Hierro, Spain.
Julio Miranda-BacalladoDepartment of Cardiology, Hospital Universitario de Canarias, Tenerife, Spain.
Alejandro de la Rosa HernándezDepartment of Cardiology, Hospital Universitario de Canarias, Tenerife, Spain.
Ignacio Laynez-CerdeñaDepartment of Cardiology, Hospital Universitario de Canarias, Tenerife, Spain.
Juan Lacalzada-AlmeidaDepartment of Cardiology, Hospital Universitario de Canarias, Tenerife, Spain.
Hospital Universitario de Canarias · ESServicio Canario de la Salud · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ischemic mitral regurgitation (IMR) is a frequent complication after acute myocardial infarction (AMI) associated with a worse prognosis. The pathophysiological mechanisms of IMR are not fully understood, but it is known to be a complex process in which ventricular remodelling is the main causal factor. The various imaging techniques in cardiology and echocardiography fundamentally have contributed significantly to clarify the mechanisms that cause and progressively aggravate IMR. At present, different therapeutic options, the most important of which are cardio-surgical, address this problem. Nowadays the improvement in cardiac surgery and transcatheter therapies, have shown a therapeutic advance in IMR management. IMR is a predictor of poor prognosis in patients with heart failure and depressed left ventricular (LV) systolic function. However, it remains controversial whether mitral regurgitation (MR) in these patients is a consequence of dilation and dysfunction of the LV, or whether it contributes to worsening the prognosis of the ventricular dysfunction. Given that echocardiography has a fundamental reference role in the identification, graduation of severity and evaluation of the therapeutics used in the treatment of MR, we are going to focus on it over the rest of the imaging techniques. In contrast to primary MR the benefits of mitral surgery in patients with secondary MR are uncertain. Therefore, we will comment fundamentally on the role of mitral surgery in patients with IMR, with an update of the different surgical interventions available, without forgetting to mention the other therapeutic options currently available.

Indexed as

diagnosisechocardiographyIschemic mitral regurgitation (IMR)management

Identifiers

PMID30746243
PMCPMC6344722
OpenAlexW2899733056

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.